Production (Stage)
Nika Pharmaceuticals, Inc.
NIKA
$0.6495
-$0.0004-0.06%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 200.00 | 200.00 | 200.00 | 200.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 200.00 | 200.00 | 200.00 | 200.00 | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 200.00 | 200.00 | 200.00 | 200.00 | -- |
| SG&A Expenses | 88.80K | 121.90K | 116.70K | 118.40K | 91.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.80K | 121.90K | 116.70K | 118.40K | 91.20K |
| Operating Income | -88.60K | -121.70K | -116.50K | -118.20K | -91.20K |
| Income Before Tax | -88.60K | -121.70K | -116.50K | -118.20K | -91.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.09 | -0.12 | -0.12 | -0.12 | -0.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.60K | -121.70K | -116.50K | -118.20K | -91.20K |
| EBIT | -88.60K | -121.70K | -116.50K | -118.20K | -91.20K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 4.09B | 3.94B | 3.79B | 3.65B | 3.50B |
| Average Diluted Shares Outstanding | 4.09B | 3.94B | 3.79B | 3.65B | 3.50B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |